CD274 and acute myeloid leukemia: Zeidan et al., in the first randomized phase 2 study in this setting, administered azacitidine 75 mg/m2 on days 1 to 7 with or without a PD-L1 inhibitor (durvalumab 1500 mg) on day 1 of every 28-day cycle in 129 older newly diagnosed AML patients and demonstrated good tolerability [83].